What is it about?
In this review, we examine drugs repurposed for the primary factors responsible for SCI pathogenesis and to counter the associated secondary complications. We also highlight adjunctive therapy options. In addition, the chemistry and molecular processes of various repurposed drugs, including those undergoing clinical trials, are highlighted. This review is aimed mainly at medical researchers, neurologists, pharmacologists, biotech and pharmaceutical industry professionals and healthcare administrators to help them find new therapeutic strategies for spinal cord injury
Featured Image
Photo by Roberto Sorin on Unsplash
Why is it important?
Drug repurposing in spinal cord injury (SCI) holds immense significance due to its potential to expedite the discovery of effective treatments while minimizing costs and risks associated with developing new drugs from scratch. Given the complex nature of SCI and the limited success of conventional treatments, repurposing existing drugs offers a promising avenue to identify compounds that could target multiple pathways involved in injury and repair mechanisms. This approach leverages the vast pool of already approved drugs for other conditions, accelerating the translation of research findings into clinical applications. Furthermore, repurposing allows for rapid clinical trials, as safety profiles and pharmacokinetics of repurposed drugs are already established, potentially bringing much-needed therapies to SCI patients more swiftly.
Perspectives
Read the Original
This page is a summary of: Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications, Pharmaceutical Medicine, September 2023, Springer Science + Business Media,
DOI: 10.1007/s40290-023-00499-3.
You can read the full text:
Resources
Contributors
The following have contributed to this page